Table 2.
Drug perturbation analysis of the overlapped DEGs.
| Gene signature | Drug name | Reported for | Mechanism of action | Phase of clinical trial | p value |
|---|---|---|---|---|---|
| CPC013_A549_6H:BRD-K69852452 (452 genes) | F-1566-0341 | Antiviral Antihistamine Drugs to treat neurological disorders | STAT inhibitor | Unknown | 1.03 × 10−13 |
| CPC017_A549_24H:BRD-K23478508 (456 genes) | Digoxin | Congestive heart failure atrial fibrillation | ATPase inhibitor | Phased | 1.39 × 10−13 |
| CPC015_A549_24H:BRD-A34806832 (446 genes) | Proscillaridin | Ocular cancer modulators of hypoxia inducible factors | Unknown | Unknown | 9.34 × 10−7 |
| CPC014_A549_24H:BRD-K99749624 (445 genes) | Linifanib | Antiarthritis Disorders of nervous system Antiglaucoma agent Ophthalmic agent |
PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | Phase III | 2.27 × 10−6 |